Antifection

Altromycin E is an antibiotic that primarily targets bacterial pathogens, demonstrating significant antibacterial activity against Streptococci and Staphylococci with a minimum inhibitory concentration (MIC) ranging from 0.2 to 3.12 μg/mL. Additionally, its properties make it a valuable compound for anti-tumor research applications.

Chuangxinmycin is an antibiotic derived from Actinoplanes tsinanensis CPCC 200056, targeting bacterial infections. It demonstrates significant antibacterial activity in both in vitro and in vivo systems, making it a valuable tool for research on infections and antibiotic efficacy. Researchers can employ Chuangxinmycin to explore mechanisms of action and resistance in bacterial pathogens.

CF3–K11 is a stable antibiotic that targets bacterial growth. It exhibits potent antibacterial activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). This compound is suitable for research applications focused on antibiotic resistance and the development of novel therapeutic strategies.

Arizonin A1 is an antibiotic that specifically targets Gram-positive bacteria. This microbial metabolite demonstrates potent antibacterial activity, making it a valuable tool for research in microbiology and antibiotic drug development. Its effectiveness against Gram-positive pathogens positions Arizonin A1 as an important compound for studies focused on bacterial resistance and therapeutic interventions.

3-O-Demethylmonensin B is a polyether antibiotic that targets a range of Gram-positive bacteria. This compound is derived from Streptomyces cinnamonensis LO-63 and exhibits potent antimicrobial activity. It is primarily utilized in microbiological studies and antibiotic research to explore its effects and mechanisms of action against resistant bacterial strains.

Endophenazine C is a phenazine antibiotic that functions by inhibiting bacterial DNA synthesis. It demonstrates potent antimicrobial activity against a range of Gram-positive and Gram-negative bacteria. This compound is primarily utilized in microbiological research to investigate bacterial resistance mechanisms and the development of novel antimicrobial agents.

Pluracidomycin B is a carbapenem antibiotic that targets bacterial cell wall synthesis. It exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria and is capable of inhibiting β-lactamase enzymes. This compound is valuable in microbiological research for investigating antibiotic resistance and evaluating bacterial susceptibility.

Gentamicin X2 is a minor aminoglycoside antibiotic that primarily targets bacterial protein synthesis by binding to the 30S ribosomal subunit. It exhibits potent antibacterial activity against a broad spectrum of Gram-negative and some Gram-positive bacteria. Gentamicin X2 is commonly utilized in microbiology research to study bacterial resistance mechanisms and to evaluate antibiotic efficacy in various therapeutic contexts.

Demethylolivomycin A is an antitumor antibiotic that primarily targets cancer cells through its ability to interfere with DNA synthesis. It exhibits significant activity against Gram-positive bacteria and demonstrates efficacy against leukemia cell lines, including P388. This compound is valuable for research focused on developing new chemotherapeutic agents and exploring antibiotic mechanisms.

Hydroxymycotrienin A is an Ansa antibiotic that targets tumor cells by inhibiting their proliferation. It demonstrates potent antitumor activity, particularly against human neck tumor cell lines, showing enhanced efficacy against human papillomavirus (HPV) gene-positive cells such as HeLa, CaSKi, and SiHa, compared to HPV gene-negative counterparts. This compound is valuable for research in cancer therapeutics and the study of HPV-related oncogenesis.

Ceforanide (lysine) is a second-generation cephalosporin that functions as a bacterial inhibitor by interfering with bacterial cell wall synthesis. It exhibits a broad spectrum of in vitro antibacterial activity against various Gram-positive and Gram-negative bacteria. Ceforanide is primarily utilized in microbiological research to study bacterial resistance and the effects of cephalosporins on different bacterial strains.

10-Decarbomethoxyaclacinomycin A is an anthracycline antibiotic that functions through the inhibition of nucleic acid synthesis. Produced by the Streptomyces galilaeus MA144-Mlt mutant strain KE303, this compound exhibits notable antibacterial activities. It is valuable for research applications focused on understanding antibacterial mechanisms and exploring potential therapeutic interventions for bacterial infections.

RPR 102341 is an antibiotic that demonstrates structural similarity to the fluoroquinolone class. It exhibits significant antibacterial activity by inhibiting bacterial DNA gyrase and topoisomerase IV, leading to disruption of DNA replication and transcription. This compound is primarily utilized in research applications focused on antibiotic resistance mechanisms and the development of novel antimicrobial agents.

Sannamycin L is an aminoglycoside antibiotic that targets bacterial protein synthesis. It exhibits weak antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a subject of interest for studying bacterial resistance mechanisms and antibiotic efficacy. This compound can be utilized in research applications focused on the development of new antimicrobial agents.

2-Hydroxy-5-iminoazacyclopent-3-ene is a pyrroline antibiotic that targets bacterial cell wall synthesis. This compound exhibits moderate antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable tool for investigating antibiotic resistance mechanisms. Research applications include studying bacterial susceptibility and the development of new antibiotic therapies.

Pyralomicin 1b is an antibiotic known for its antibacterial activity. It acts by inhibiting bacterial protein synthesis, making it effective against a range of Gram-positive pathogens. This compound is valuable for research focused on bacterial resistance mechanisms and the development of new antimicrobial agents.

Chitotriose is a chitooligosaccharide derived from chitosan obtained from crab shells. It exhibits antibacterial activity specifically against Salmonella species. This compound is valuable for research applications in studying antimicrobial mechanisms and the development of antibacterial agents.

44-Homooligomycin A is an antitumor antibiotic that primarily targets fungal pathogens, demonstrating notable activity against species such as Aspergillus, Penicillium, and Fusarium. This compound shows limited efficacy against yeast and bacteria. In preclinical studies, 44-Homooligomycin A exhibits moderate antitumor activity against the Colon 26 cell line in vivo, making it a candidate for further investigation in cancer research and antifungal therapeutics.

Pyloricidin B is an antibiotic that specifically targets Helicobacter pylori. It exhibits significant antibacterial activity against this pathogen, making it a valuable tool for research related to gastric infections and related conditions. Pyloricidin B demonstrates selectivity, showing no activity against other bacterial species or yeast, highlighting its potential utility in studying H. pylori-related diseases.

4-O-Demethyl-11-deoxydoxorubicin is an anthracycline antibiotic that primarily targets DNA, resulting in the inhibition of topoisomerase II activity. It exhibits significant cytotoxicity against various cancer cell lines, including HeLa cells. This compound is utilized in research focusing on anti-cancer mechanisms and the development of novel therapeutic strategies.

Seitomycin is an anthraquinone antibiotic that primarily targets bacterial cells. It exhibits moderate antimicrobial activity against a range of Gram-positive bacteria, including Staphylococcus aureus and Bacillus subtilis, as well as Gram-negative bacteria such as Escherichia coli and Streptomyces chlorophyllus. This compound is relevant for research applications focusing on antibiotic susceptibility, bacterial resistance mechanisms, and the development of new antimicrobial agents.

Nebramycin V' is a multi-component aminoglycoside antibiotic that primarily targets bacterial ribosomes, inhibiting protein synthesis. It exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as mycobacteria. This makes it valuable for research applications related to antimicrobial resistance, bacterial infections, and the study of protein synthesis mechanisms.

Noboritomycins A is a polyether antibiotic that primarily targets Gram-positive bacteria. It exhibits antimicrobial activity, making it a valuable compound in the study of bacterial infections. Additionally, Noboritomycins A demonstrates weak anti-coccidial effects, which may be of interest in research related to parasitic diseases.

4-Hydroxyphlebiarubrone is a quinone antibiotic that exhibits activity against certain bacterial strains. It demonstrates weak resistance to Gram-negative bacteria, making it of interest in studies related to antibiotic resistance mechanisms. Additionally, its cytotoxic properties warrant further investigation in cellular biology and cancer research applications.

Armentomycin is a non-protein amino acid with potent antibiotic properties, primarily targeting Gram-negative bacteria. Its mechanism of action involves inhibition of bacterial growth, making it a valuable reagent for research focused on antibiotic efficacy and resistance mechanisms. Armentomycin serves as a critical tool for studies investigating microbial infections and developing novel antimicrobial strategies.

Parvodicin C3 is a glycopeptide antibiotic that exerts its antimicrobial activity by inhibiting bacterial cell wall synthesis. It demonstrates potent activity against various gram-positive pathogens, including Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus, and Enterococcus faecalis. This compound is valuable for research applications focused on bacterial resistance mechanisms and the development of new antibacterial agents.

4-Hydroxybaumycinol A1 is an anthracycline antibiotic that exerts its primary mechanism through DNA intercalation, leading to the inhibition of topoisomerase II. This compound demonstrates significant antitumor activity, making it a valuable reagent for cancer research. Its potent effects on tumor cell proliferation position it as a useful tool in studies aimed at understanding and developing new cancer therapies.

Antibacterial agent 266 is an antibiotic that targets bacterial integrity, effectively inhibiting plant pathogens. It demonstrates notable activity with EC50 values of 24.1 μg/mL against Xanthomonas oryzae pv oryzae and 39.0 μg/mL against Xanthomonas axonopodis pv citri. This reagent is valuable for research in plant pathology and the development of agricultural antimicrobial agents.

Maridomycin II is a macrolide antibiotic that targets bacterial protein synthesis. It exhibits potent activity against Gram-positive bacteria and mycoplasma, making it a valuable tool for studying bacterial infections. Additionally, Maridomycin II has demonstrated protective effects in murine models of Gram-positive bacterial infections, highlighting its potential utility in infectious disease research.

Milbemycin α14 is an antibiotic that exerts its effects by effectively targeting and eliminating nematodes and mites. This compound is commonly used in research applications focusing on parasitic infections and pest control, providing a valuable tool for biologists studying the mechanisms of action of antiparasitic agents.

Fluvirucin A2 is an antibiotic specifically targeting the influenza A virus. It demonstrates potent antiviral activity, disrupting viral replication and reducing infection severity. This compound is valuable for research applications investigating antiviral strategies and the mechanisms of influenza pathogenesis.

Halymecin A is an antibiotic derived from marine microbes, primarily targeting bacterial and fungal pathogens. Although it exhibits only weak antibacterial and antifungal activity, it serves as a valuable tool for studies in microbial interactions and the exploration of novel antibacterial compounds. This compound's unique origin and modest bioactivity make it relevant for research in natural product chemistry and antibiotic development.

Atramycin A is an isotetracenone-based antitumor antibiotic that exhibits potent cytotoxic activity against various cancer cell lines. Its mechanism involves DNA intercalation and the inhibition of topoisomerase II, leading to disruptions in DNA replication and cellular proliferation. Atramycin A is valuable for research applications focused on cancer biology and the development of new antitumor therapies.

Cystothiazole B is a bithiazole-type antibiotic that exhibits antimicrobial activity by inhibiting bacterial protein synthesis. It is primarily extracted from the organism Cystobacter fuscus. This compound is utilized in research applications focused on antibacterial mechanisms and the identification of novel antibiotics.

Deoxypheganomycin D is a specific antimycobacterial agent that demonstrates selective inhibition of Mycobacterium 607 growth without cross-resistance to other antibiotics. At a concentration of 28 μM, it significantly reduces bacterial proliferation while showing minimal impact on DNA, RNA, or protein synthesis pathways. Notably, at 7 μM, Deoxypheganomycin D interferes with leucine influx and alters efflux dynamics, suggesting its action may involve interactions with the cell membrane and distinct mycobacterial lipid components. This reagent is valuable for researchers studying mycobacterial resistance mechanisms and developing alternative treatment strategies.

Sakyomicin A is an antibiotic derived from the Actinomycete strain M-53, primarily targeting Gram-positive bacteria. This compound demonstrates significant antibacterial activity, making it valuable for research applications focused on microbial resistance and antibiotic efficacy. Its unique mechanism of action facilitates the exploration of new therapeutic options against Gram-positive infections.

6-Deoxyilludin M is an antitumor antibiotic that exhibits significant antileukemic activity. This compound can be isolated from the culture broth of the Basidiomycota species, Pleurotus japonicus. It serves as a valuable tool for cancer research, particularly in studies aimed at understanding leukemic processes and developing novel therapeutic strategies.

Feudomycin A is an antitumor antibiotic that inhibits cancer cell proliferation through its unique cyclic structure. Its biological activity includes the induction of apoptosis in various tumor cell lines, thereby demonstrating potential in cancer research and therapeutic applications. Investigations into its mechanistic pathways can facilitate the development of novel anticancer strategies.

Epithienamycin A is a carbapenem antibiotic that exerts its action by inhibiting bacterial cell wall synthesis. It demonstrates significant antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable compound for research in antibiotic efficacy and resistance studies. This reagent is useful for evaluating the mechanisms of bacterial susceptibility and potential therapeutic applications in infectious disease management.

Biphenomycin A is a cyclic peptide antibiotic derived from Streptomyces griseorubiginosus 43708. It exhibits significant antibacterial activity and is relevant for research in the field of anti-infection. Its unique structure and mechanism offer potential insights into antibiotic development and resistance studies.

CS 461 is a cephalosporin antibiotic that exhibits potent antibacterial activity against both Gram-positive and Gram-negative bacteria, including certain β-lactamase producing strains. This compound is valuable for research focused on infections, providing a well-balanced approach to tackling diverse bacterial pathogens. Its utility in understanding antibacterial mechanisms makes it a significant reagent in the study of antibiotic resistance and infection treatment strategies.

Gentamicin C1 is an aminoglycoside antibiotic that primarily targets bacterial ribosomes to inhibit protein synthesis. It exhibits broad-spectrum antimicrobial activity effective against a variety of Gram-negative and some Gram-positive bacteria. This compound is widely used in research and clinical settings for the treatment of serious infections and for studying antibiotic resistance mechanisms.

Arylomycin A5 is a lipohexapeptide antibiotic that targets Gram-positive bacteria through inhibition of bacterial protein synthesis. It demonstrates significant antibacterial activity by interfering with the function of ribosomal RNA, making it a valuable tool in the study of antibiotic resistance and bacterial infections. Arylomycin A5 is suitable for research applications aimed at elucidating the mechanisms of action of antibiotics and developing new therapeutic strategies.

(1S,2R,7S)-Sitafloxacin is an antibiotic with potent topoisomerase inhibition targeting DNA gyrase and topoisomerase IV in bacteria. It exhibits significant antibacterial activity, with an IC50 of 0.18 μg/mL against Escherichia coli DNA gyrase and effective action against Staphylococcus aureus. This compound is valuable in the study of various bacterial infections and provides insights into antibiotic resistance mechanisms and therapeutic approaches.

Napyradiomycin C1 is an antibiotic that exhibits potent activity against Gram-positive bacteria and mycobacterial strains. It demonstrates minimal efficacy against Gram-negative bacteria and fungi. The compound shows an IC50 of 9.2 µg/mL in leukemia L-1210 cells, indicating its potential application in cancer research and the development of novel therapeutic strategies against specific bacterial infections.

Auramycin A is an anthracycline antibiotic targeting Gram-positive bacteria, demonstrating significant antibacterial activity. In addition to its antimicrobial properties, Auramycin A exhibits notable antitumor effects against P388 and L1210 leukemia cell lines in murine models, making it a valuable reagent for research in both infectious diseases and cancer therapies.

Pristinamycin IB is an ester peptide antibiotic primarily targeting Gram-positive bacteria. Its mechanism involves inhibiting protein synthesis, leading to antimicrobial activity. Pristinamycin IB is used in research applications aimed at understanding bacterial resistance and testing new therapeutic approaches against resistant strains of Gram-positive pathogens.

Haloquinone is a quinone antibiotic that demonstrates potent antibacterial activity against Halobacteria, as well as exhibiting effects against Gram-positive bacteria and mycoplasma. This compound is valuable in researching bacterial resistance mechanisms and the efficacy of novel antibiotic therapies. Its broad-spectrum activity makes it a useful tool for microbiological studies and drug development in the field of infectious diseases.

Baumycin C1 is an antitumor antibiotic that exerts its biological activity through the inhibition of DNA synthesis. This compound demonstrates potent cytotoxic effects against various cancer cell lines, making it a valuable tool for cancer research. Its mechanism of action and efficacy position Baumycin C1 as a potential candidate for studies investigating novel antitumor therapies.

Sperabillin C is an antimicrobial antibiotic that exhibits potent activity against both Gram-negative and Gram-positive bacteria, including resistant strains such as Pseudomonas aeruginosa and Staphylococcus aureus. Its ability to target a wide spectrum of bacterial pathogens makes it a valuable reagent for research applications in antibiotic resistance studies and the development of new antimicrobial therapies.